Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
huMNC2-CAR44 or huMNC2-CAR22 in Advanced MUC1* Positive Breast Cancer
NCT04020575Phase 1Recruiting
- Sponsor
- Minerva Biotechnologies
- Start
- Jan 2020
- Primary completion
- Jan 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of huMNC2-CAR44 and huMNC2-CAR v2b (1XX modified) in breast cancer (4 arms), sponsored by Minerva Biotechnologies. Primary endpoint: Incidence of Adverse Events at 35 days. Started Jan 2020; status: recruiting.
02
Drugs
huMNC2-CAR44huMNC2-CAR v2b (1XX modified)
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04020575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04020575.